| Literature DB >> 34843536 |
Marcelo Dantas Tavares de Melo1, Jose de Arimatéia Batista Araujo-Filho2, José Raimundo Barbosa3, Camila Rocon1,2, Carlos Danilo Miranda Regis3, Alex Dos Santos Felix4, Roberto Kalil Filho1,2, Edimar Alcides Bocchi1, Ludhmila Abrahão Hajjar1, Mahdi Tabassian5, Jan D'hooge5, Vera Maria Cury Salemi1,2.
Abstract
AIMS: Noncompaction cardiomyopathy (NCC) is considered a genetic cardiomyopathy with unknown pathophysiological mechanisms. We propose to evaluate echocardiographic predictors for rigid body rotation (RBR) in NCC using a machine learning (ML) based model. METHODS ANDEntities:
Mesh:
Year: 2021 PMID: 34843536 PMCID: PMC8629285 DOI: 10.1371/journal.pone.0260195
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Fig 1Apical rotation and basal rotation curve obtained from NCC patients.
Normal left ventricular torsion (A), and rigid body rotation pattern (B). The green line represents the apex rotation, and the basal rotation is showed in pink, while the curves mean represented in white. Ordinate axis with positive value expresses counterclockwise rotation and with a negative value, clockwise rotation. AVC, aortic valve closure; LV twist = apical rotation–basal rotation (white line).
Fig 2Task execution diagram from the data acquisition to the results of noncompaction cardiomyopathy patients.
Demographic, clinical, and laboratory data of noncompaction patients.
| Patient characteristics | All patients ( | LV-RBR absent ( | LV-RBR present ( | ||
|---|---|---|---|---|---|
| Gender (male), n (%) | 21 (42.9) | 10 (37.0) | 11 (50.0) | 0.534 | |
| Age (years) | 42.8 (14.8) | 43.8 (12.6) | 41.5 (17.3) | 0.596 | |
| Body surface area (m2) | 1.76 (0.21) | 1.81 (0.17) | 1.69 (0.24) | 0.068 | |
| NYHA, n (%) | I | 39 (79.6) | 22 (81.5) | 17 (77.3) | 0.868 |
| II | 7 (14.3) | 3 (11.1) | 4 (18.2) | 0.238 | |
| III | 3 (6.12) | 2 (7.41) | 1 (4.55) | 0.037 | |
| Diabetes mellitus, n (%) | 3 (6.12) | 3 (11.1) | 0 (0.00) | 0.242 | |
| Smokers, n (%) | 3 (6.12) | 2 (7.41) | 1 (4.55) | 1.000 | |
| Systemic arterial hypertension, n (%) | 13 (26.5) | 8 (29.6) | 5 (22.7) | 0.827 | |
| Ventricular tachycardia, n (%) | 7 (14.3) | 4 (14.8) | 3 (13.6) | 1.000 | |
| Family history of NCC, n (%) | 24 (49.0) | 15 (55.6) | 9 (40.9) | 0.464 | |
| History of embolic events, n (%) | 1 (2.04) | 0 (0.00) | 1 (4.55) | 0.449 | |
| ACE-inhibitor, n (%) | 42 (85.7) | 22 (81.5) | 20 (90.9) | 0.436 | |
|
|
|
|
|
| |
| Beta blocking agent, n(%) | 39 (79.6) | 19 (70.4) | 20 (90.9) | 0.152 | |
| Serum creatinine (mg/dL) | 0.90 (0.20) | 0.91 (0.21) | 0.88 (0.19) | 0.593 | |
ACE: angiotensin-converting enzyme; LV-RBR: left ventricular rigid body rotation; NCC: noncompaction cardiomyopathy; NYHA: New York Heart Association (functional class).
Echocardiographic parameters evaluated in noncompaction cardiomyopathy with rigid body rotation and included in the prediction model.
| Echocardiographic features, n (%) | All patients ( | LV-RBR absent ( | LV-RBR present ( | ||
|---|---|---|---|---|---|
| LV mass (g) | 183 (63.3) | 171 (54.1) | 198 (71.6) | 0.152 | |
|
| 105 (36.9) | 94.1 (27.1) | 118 (43.4) | 0.034 | |
|
| 52.0 (7.39) | 49.3 (6.20) | 55.4 (7.45) | 0.004 | |
| RV basal (mm) | 34.9 (6.16) | 34.0 (4.83) | 36.0 (7.44) | 0.265 | |
|
| 21.7 (4.35) | 23.2 (3.53) | 19.7 (4.55) | 0.005 | |
| S’ RV (cm/s) | 13.2 (2.64) | 13.8 (2.06) | 12.3 (3.10) | 0.068 | |
| FAC (%) | 49.2 (10.8) | 47.3 (8.56) | 51.4 (12.8) | 0.202 | |
| LAI (mL/m2) | 35.2 (14.8) | 32.6 (14.1) | 38.4 (15.4) | 0.184 | |
| E (cm/s) | 76.4 (23.9) | 73.1 (21.3) | 80.5 (26.8) | 0.314 | |
| A (cm/s) | 59.1 (19.7) | 57.5 (17.1) | 61.2 (22.8) | 0.532 | |
| E/A | 1.37 (0.44) | 1.32 (0.36) | 1.43 (0.53) | 0.416 | |
| DT (ms) | 219 (85.8) | 202 (78.3) | 239 (92.3) | 0.155 | |
| TRIV (ms) | 111 (25.3) | 109 (28.6) | 113 (21.0) | 0.640 | |
| e’ (cm/s) | 9.78 (4.40) | 10.7 (4.43) | 8.60 (4.16) | 0.097 | |
|
| 9.73 (6.58) | 7.69 (3.13) | 12.2 (8.68) | 0.031 | |
| Tricuspid velocity peak (m/s) | 3.26 (4.67) | 2.46 (0.68) | 4.02 (6.47) | 0.354 | |
|
| 71.1 (34.0) | 53.6 (14.1) | 92.7 (38.9) | <0.001 | |
|
| 38.1 (28.0) | 22.5 (9.71) | 57.2 (31.3) | <0.001 | |
|
| 50.7 (12.6) | 58.9 (8.76) | 40.7 (8.71) | <0.001 | |
|
| 15.4 (4.67) | 17.9 (3.74) | 12.2 (3.72) | <0.001 | |
|
| 9.40 (8.32) | 15.2 (6.25) | 2.32 (3.82) | <0.001 | |
|
| 1.16 (1.05) | 1.89 (0.81) | 0.27 (0.45) | <0.001 | |
| LAS reservoir (%) | 30.6 (11.5) | 32.3 (10.8) | 28.5 (12.2) | 0.256 | |
| LAS booster (%) | 12.1 (6.09) | 12.6 (6.05) | 11.5 (6.22) | 0.517 | |
| LAS conduit (%) | 18.1 (9.40) | 19.6 (9.22) | 16.2 (9.50) | 0.213 | |
| 23.0 (7.50) | 24.1 (5.55) | 21.6 (9.30) | 0.265 | ||
|
| 26.3 (14.9) | 33.2 (14.0) | 17.9 (11.6) | <0.001 | |
| LVRS mid (%) | 26.9 (15.5) | 30.0 (15.4) | 23.1 (15.1) | 0.121 | |
| LVRS apical (%) | 22.8 (18.5) | 23.7 (13.7) | 21.7 (23.4) | 0.720 | |
|
| 25.3 (11.5) | 29.0 (10.8) | 20.9 (11.1) | 0.014 | |
|
| 11.0 (6.32) | 13.2 (4.95) | 8.16 (6.79) | 0.006 | |
|
| 11.5 (6.18) | 13.2 (4.76) | 9.53 (7.18) | 0.049 | |
|
| 13.7 (7.69) | 17.0 (6.23) | 9.57 (7.44) | 0.001 | |
|
| 12.1 (6.16) | 14.5 (4.37) | 9.22 (6.88) | 0.004 | |
|
| 0.22 (0.42) | 0.11 (0.32) | 0.36 (0.49) | 0.046 | |
| NC/C | 2.99 (±0.99) | 2.3 (±0.15) | 3.72 (±0.98) | 0.13 | |
| LV (%) remodeling | CH | 6 (12.2) | 4 (14.8) | 2 (9.09) | 0.940 |
| CR | 4 (8.16) | 2 (7.41) | 2 (9.09) | 0.572 | |
| EH | 16 (32.7) | 8 (29.6) | 8 (36.4) | 0.940 | |
| normal | 23 (46.9) | 13 (48.1) | 10 (45.5) | 0.957 | |
CH, concentric hypertrophy; CR, concentric remodeling; DT, deceleration time; EH, eccentric hypertrophy; FAC, fractional area change; IRVT, isovolumic relaxation time; LAI, left atrium volume indexed; LAS, left atrium strain; LV, left ventricle; LVDD, left ventricular diastolic diameter; LV EDVI, left ventricular end-diastolic volume indexed; LVEF, left ventricle ejection fraction; LVCS, left ventricular circumferential strain; LV ESVI, left ventricular end-systolic volume indexed; LV GCS, left ventricular global circumferential strain; LV GLS, left ventricular global longitudinal strain; LV GRS, left ventricular global radial strain; LVIM, left ventricular mass indexed; LVRS, left ventricular radial strain; NC/C, noncompacted/compacted ratio; RBR, left ventricular rigid body rotation; RV, right ventricle; RV FWS, right ventricle free wall strain; TAPSE, tricuspid annular plane systolic excursion.
Fig 3Pearson’s correlation matrix is ordered from the coefficients between the features and rigid body rotation.
Fig 4Echocardiographic features in decreasing order of importance to rigid body rotation in noncompaction cardiomyopathy patients.
Fig 5ROC curves for prediction model to rigid body rotation pattern in noncompaction cardiomyopathy patients.
The continuous blue line shows the ROC curve obtained from the model’s performance during the training stage. The dashed orange line shows the ROC curve obtained during the test step.